Glycovax Pharma launches a highly performant SLA Adjuvant

Glycovax Pharma Inc. is starting the large-scale production of a new glycolipidic vaccine adjuvant developed by the National Research Council of Canada (NRC). The NRC license has allowed Glycovax to optimize SLA manufacturing by developing a fully synthetic process meeting Good Manufacturing Practices (GMP).

Continue reading…

Posted in